Susceptibility of influenza viruses to hypothiocyanite and hypoiodite produced by lactoperoxidase in a cell-free system

Urmi Patel, Aaron Gingerich, Lauren Widman, Demba Sarr, Ralph A. Tripp, Balázs Rada*
University of Georgia, College of Veterinary Medicine, Department of Infectious Diseases, Athens, Georgia, United States of America

* radab@uga.edu

Abstract

Lactoperoxidase (LPO) is an enzyme found in several exocrine secretions including the airway surface liquid producing antimicrobial substances from mainly halide and pseudohalide substrates. Although the innate immune function of LPO has been documented against several microbes, a detailed characterization of its mechanism of action against influenza viruses is still missing. Our aim was to study the antiviral effect and substrate specificity of LPO to inactivate influenza viruses using a cell-free experimental system. Inactivation of different influenza virus strains was measured in vitro system containing LPO, its substrates, thiocyanate (SCN⁻) or iodide (I⁻), and the hydrogen peroxide (H₂O₂)-producing system, glucose and glucose oxidase (GO). Physiologically relevant concentrations of the components of the LPO/H₂O₂/(SCN⁻/I⁻) antimicrobial system were exposed to twelve different strains of influenza A and B viruses in vitro and viral inactivation was assessed by determining plaque-forming units of non-inactivated viruses using Madin-Darby canine kidney cells (MDCK) cells. Our data show that LPO is capable of inactivating all influenza virus strains tested: H1N1, H1N2 and H3N2 influenza A viruses (IAV) and influenza B viruses (IBV) of both, Yamagata and Victoria lineages. The extent of viral inactivation, however, varied among the strains and was in part dependent on the LPO substrate. Inactivation of H1N1 and H1N2 viruses by LPO showed no substrate preference, whereas H3N2 influenza strains were inactivated significantly more efficiently when iodide, not thiocyanate, was the LPO substrate. Although LPO-mediated inactivation of the influenza B strains tested was strain-dependent, it showed slight preference towards thiocyanate as the substrate. The results presented here show that the LPO/H₂O₂/(SCN⁻/I⁻) cell-free, in vitro experimental system is a functional tool to study the specificity, efficiency and the molecular mechanism of action of influenza inactivation by LPO. These studies tested the hypothesis that influenza strains are all susceptible to the LPO-based antiviral system but exhibit differences in their substrate specificities. We propose that a LPO-based antiviral system is an important contributor to anti-influenza virus defense of the airways.
Introduction

Influenza virus epidemics and periodic pandemics affect millions of people worldwide causing serious substantial morbidity and mortality representing a major economic burden [1, 2]. Current prophylactic options are problematic due to the yearly need for strain-specific vaccination, the development of drug resistance, and changes in the virus related to antigenic drift and viral reassortment [3–5]. Identifying novel antiviral approaches that are broadly effective against several influenza strains is urgently needed. In this regard, the respiratory innate immune system could possess such mechanisms.

Bronchial epithelial cells (BEC) are a primary target for influenza virus replication [6]. Early response by BECs to influenza virus is crucial in determining progression of viral infection, adaptive immunity, and lung pathogenesis [7]. BECs orchestrate an oxidative extracellular antimicrobial system present in the airway surface liquid consisting of LPO, its main natural substrate, the thiocyanate anion (SCN⁻) and hydrogen peroxide (H₂O₂) (Fig 1) [8–11]. LPO is an abundant peroxidase in the airways that uses H₂O₂ to oxidize its most abundant and preferred substrate, SCN⁻, into hypothiocyanite (OSCN⁻) [12]. Hypothiocyanite is a short-lived, antimicrobial agent that is not toxic to the host and has been shown to kill several microbes, mainly bacteria. Its antiviral action remains, however, less characterized and understood.

Hypothiocyanite was shown to inactivate the A/H1N1 2009 pandemic influenza virus in a cell-free system [13]. We also reported that OSCN⁻ generated on the apical surface of BECs is capable of inactivating the A/swine/Illinois/02860/09 (swH1N2) influenza A strain [9]. These

---

**Fig 1. Description of the cell-free in vitro experimental system producing antiviral hypothiocyanite or hypoiodite.** We established an in vitro experimental system to study the antiviral action of the LPO/H₂O₂/(SCN⁻/I⁻) system in the absence of epithelial cells. H₂O₂ is generated in the enzymatic reaction of GO turning D-glucose into D-gluconate. Produced H₂O₂ is used by LPO to oxidize its potential substrates, SCN⁻ or I⁻. The products of the enzymatic action of LPO are either OSCN⁻ or OI⁻, depending on the substrate used. Both, OSCN⁻ or OI⁻ have virucidal effects on influenza viruses. Physiologically relevant concentrations of LPO (6.5 μg/ml), SCN⁻ or I⁻ (400 μM), glucose (5 mM) and glucose oxidase (0.01 U/ml) are used. SCN⁻, thiocyanate; OSCN⁻, hypothiocyanite; I⁻, iodide; OI⁻, hypoiodite; LPO, lactoperoxidase; GO, glucose oxidase.

https://doi.org/10.1371/journal.pone.0199167.g001
observations suggest that the H$_2$O$_2$/LPO/SCN$^-$ system is an important contributor to anti-influenza viral defense of the respiratory immune system, and imply that this innate response could be utilized to enhance early clearance of influenza virus perhaps in a strain-independent manner. To better understand the anti-influenza virus action of this oxidative system, we aimed at characterizing its virus-inactivating effect by testing several influenza virus strains. In addition to its natural substrate, SCN$^-$, we also tested iodide (I$^-$), as LPO substrate to study the substrate specificity of the antiviral action of LPO. LPO readily oxidizes several halides and pseudohalides using H$_2$O$_2$ [14]. Iodide is considered to be a better LPO substrate than SCN$^-$ to inhibit growth of certain fungi and bacteria [15, 16]. In this study, we tested an in vitro, cell-free experimental system to characterize the anti-influenza virus action and substrate specificity of LPO. We found that LPO inactivates a wide-range of influenza strains, but surprisingly the extent of LPO-mediated viral inactivation and LPO substrate preference differed among tested isolates.

**Materials and methods**

**Influenza A and B strains**

Influenza A and B strains used in this work were purchased from the NIH Biodefense and Emerging Infections Research Resources Repository, NIAID, NIH (BEI Resources) and are listed in Table 1. Influenza viruses were propagated in Madin-Darby Canine Kidney (MDCK) cells (ATCC® CCL-34™) as described [9]. Briefly, MDCK cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) containing high glucose (HyClone) supplemented with 5% heat-inactivated fetal bovine serum (FBS; HyClone) and maintained at 37˚C with 5% CO$_2$. Viral strains were cultured in MDCK cells using infection medium (DMEM containing high glucose supplemented with 1 mM L-glutamine with 1-μg/ml tosylsulfonyl phenylalanyl chloromethyl ketone [TPCK]-treated trypsin). Viruses were collected 24–48 hours post-infection.

**Cell-free viral inactivation assay**

Components of the LPO-based antiviral system were used at the following concentrations: 6.5 μg/ml LPO, 400 μM SCN$^-$/I$^-$, glucose (0.005 M) and glucose oxidase 0.01 U/mL. The reaction volume was set to 40 μL with the appropriate concentration of each component.

| Table 1. | Influenza virus strains used in this work. |
|----------------|------------------------------------------|
| Viral strain    | Viral species | Serotype/subtype |
| A/Brisbane/59/2007 | IAV          | H1N1            |
| A/California/04/2009 | IAV          | H1N1            |
| A/Mississippi/3/2001 | IAV          | H1N1            |
| A/Turkey/Kansas/4880/1980 | IAV       | H1N1            |
| A/Swine/Illinois/02860/2009 | IAV       | H1N2            |
| A/Texas/50/2012 | IAV          | H3N2            |
| A/Wisconsin/67/2005 | IAV          | H3N2            |
| A/Aichi/2/1968 | IAV          | H3N2            |
| A/Hong Kong/8/1968 | IAV          | H3N2            |
| B/Yamagata/16/1988 | IBV          | Yamagata        |
| B/Great Lakes/1739/1954 | IBV       | Yamagata        |
| B/New York/1056/2003 | IBV          | Victoria        |

IAV, Influenza A virus; IBV, Influenza B virus. Viruses were purchased from BEI Resources.

https://doi.org/10.1371/journal.pone.0199167.t001
mentioned above. Catalase (700 U/mL, Sigma-Aldrich, St. Louis, MO) was also used when indicated to inhibit the system. The components were assembled in a sterile Eppendorf tube with the virus being added last. The tubes were then placed on a 37°C heating block for one hour. After the incubation, supernatants were stored at -80°C. Plaque assays were performed on MDCK cells to determine viral concentrations as previously described [9, 17]. This assay is the "cell-free" version of the viral inactivation assay established previously on primary airway epithelial cells with the main difference that the source of H$_2$O$_2$ here is the glucose/GO enzymatic reaction compared to Dual oxidase 1 in epithelial cells [9].

Statistics
Data for the viral inactivation assay were log$_{10}$-transformed and significance was calculated using a one-way ANOVA followed by Tukey or Dunn's multiple comparison post-hoc test when more than two samples were compared. When virus inactivation or the substrate preference ratios were compared between two LPO substrates or influenza subtypes or species, Mann-Whitney test was used. Statistical analysis was performed using Prism 6 for Windows version 6.07 software. *, p<0.05; **, p<0.01; ***, p<0.001.

Results
Optimization of the cell-free, in vitro H$_2$O$_2$/LPO/(SCN$^-$/I$^-$) experimental system
LPO is produced by submucosal glands and epithelial cells in the respiratory tract and it accumulates in the airway surface liquid [18, 19]. LPO concentration in airway secretions has been estimated to be in the range of 3–12 μg/ml [18]. We used a physiologically relevant LPO concentration of 6.5 μg/ml in our cell-free assay [20]. Thiocyanate is present in airway secretions in submillimolar concentrations [12, 18]. Accordingly, we used 400 μM SCN$^-$ in the in vitro assay, and used 400 μM iodide as alternative LPO substrate. The same LPO and SCN$^-$ concentrations were used as previously published in our prior studies using primary bronchial epithelial cells to make results comparable between the cell-free system and epithelial cultures [9]. While H$_2$O$_2$ has been detected in airway secretions of humans and other mammalian species, estimating its basal levels is difficult due to its volatile nature. The main in vivo sources of H$_2$O$_2$ in the airways are NADPH oxidases called Dual Oxidase 1 and 2 (Duox 1/2) [8]. Duox enzymes are highly expressed in the apical plasma membrane of BECs and generate H$_2$O$_2$ directly into the airway surface liquid [8]. In our in vitro system containing BECs, Duox enzymes generate H$_2$O$_2$ driving the antimicrobial action of LPO [9, 20, 21]. In the cell-free system described here, H$_2$O$_2$ is provided by the enzymatic reaction of glucose (5 mM) and glucose oxidase (GO) that produces D-gluconic acid as the end product (Fig 1) [20]. Generating H$_2$O$_2$ by an enzymatic reaction better models the slow but maintained nature and kinetics of H$_2$O$_2$ release by BECs than a bolus-like addition of H$_2$O$_2$ [20, 21]. To mimic the H$_2$O$_2$ output of BECs in the cell-free system, we titrated the dose of GO and chose 0.01 U/ml, a concentration that is the closest to the hourly H$_2$O$_2$ production of BECs [9, 20, 21] (data not shown). Thus, the components of the cell-free system are used in concentrations that are physiologically relevant.

The cell-free H$_2$O$_2$/LPO/(SCN$^-$/I$^-$) system inactivates the A/Swine/Illinois/02860/2009 H1N2 influenza virus
We have shown previously that BECs are capable of inactivating the A/Swine/Illinois/02860/2009 (H1N2) influenza A strain (Table 1) in a H$_2$O$_2$ (Duox)$^+$, LPO-$^+$ and SCN$^-$$^+$-dependent
manner [9]. Next we wanted to confirm this in the cell-free system. As shown in Fig 2A, the H$_2$O$_2$/LPO/(SCN$^-$/I$^-$) cell-free system had also a strong and substantial inactivating effect on the A/Swine/Illinois/02860/2009 (H1N2) influenza A virus. Viruses were incubated in the presence or absence of the components of the cell-free system as indicated for 1 hour when (A) SCN$^-$ or (B) I$^-$ was used as LPO substrate. Viral inactivation was assessed by plate-forming unit assay using MDCK cells. Mean+/−S.E.M., n = 4–5. (C) SCN$^-$ and I$^-$ dose-dependence of A/Swine/Illinois/02860/2009 inactivation. Mean+/−S.E.M., n = 3. One-way ANOVA, Tukey’ multiple comparison test. Ns, non-significant, **, p<0.01; ***, p<0.001. SCN$, thiocyanate; OSCN$, hypothiocyanite; I$, iodide; OI$, hypoiodite; LPO, lactoperoxidase; GO, glucose oxidase; MDCK, Madin-Darby canine kidney cells; PFU, plaque-forming unit.

https://doi.org/10.1371/journal.pone.0199167.g002

Next, we tested how H1N2 inactivation by the cell-free system changes if I$^-$ (an alternative LPO substrate) is used. I$^-$ has been shown to enhance the antiviral activity of LPO against adenovirus and respiratory syncytial viruses [15, 22]. I$^-$ was used at the same concentration as SCN$^-$ (400 μM). Replacing SCN$^-$ with I$^-$ in the cell-free system led to even more effective H1N2 inactivation (Fig 2A). Similar to results obtained with SCN$, catalase blocked viral inactivation when I$^-$ was used (Fig 2B). Omitting any of the components of the I$^-$ based cell-free system resulted in complete loss of H1N2 inactivation confirming that hypoiodite (OI$^-$) is responsible for the virucidal effect (Fig 2B). To better characterize the substrate preference of LPO in inactivating H1N2, we tested viral inactivation at doses of SCN$^-$ and I$^-$ lower than 400 μM. As the dose-dependence curves shown in Fig 2C indicate, H1N2 was more susceptible to I$^-$ mediated...
inactivation by the cell-free system. Interestingly, sensitivity to OSCN\(^-\) drops drastically at SCN\(^-\) doses just below 100 \(\mu\)M (Fig 2C). Results presented here confirm that the cell-free system serves as a good model to study influenza inactivation by the \(\text{H}_2\text{O}_2/\text{LPO}/\text{SCN}^-\) system, and the swine H1N2 strain tested is susceptible to both, OSCN\(^-\) and OI\(^-\) mediated inactivation by LPO, with a slightly higher sensitivity to OI\(^-\).

**H1N1 influenza A strains are inactivated by LPO in a substrate-independent manner**

Influenza A viruses are classified based on two of their surface proteins, hemagglutinin (HA) and neuraminidase (NA), that also determine their antigenic specificities. Since the H1N1 and H3N2 serotypes have been commonly present in human epidemics and pandemics over the last century [23], it was important to compare several H1N1 and H3N2 strains in the cell-free system for LPO-mediated inactivation (Table 1). The IAV H1N1 strains, A/Brisbane/59/2007, A/California/04/2009 and A/Mississippi/3/2001 (Table 1), cause seasonal influenza virus infections in humans while the A/Turkey/Kansas/4880/1980 H1N1 strain is a virus of swine antigenic phenotype isolated from turkeys [23–25]. We tested A/Brisbane/59/2007 and observed a 1.31+/-0.42 (mean+/-S.E.M., \(n = 3\)) log (SCN\(^-\)) and a 1.06+/-0.28 (mean+/-S.E.M., \(n = 3\)) log (I\(^-\)) inactivation by the cell-free system, respectively (Fig 3A). The extent of OSCN\(^-\)-mediated viral inactivation was significant (\(p = 0.011\)) while that of OI\(^-\) was not (\(p = 0.090\)) (Fig 3A). Catalase had an inhibitory but non-significant (\(p = 0.092\)) and incomplete effect on viral inactivation for both substrates (Fig 3A). Both LPO substrates mediated A/California/04/2009 viral inactivation beyond detection limit of the assay in the cell-free system which was highly significant (\(p<0.0001\), for each substrate) (Fig 3A). Removing \(\text{H}_2\text{O}_2\) by catalase treatment significantly reversed (\(p<0.0001\)) the virus-inactivating effect of LPO by both substrates (Fig 3A). The A/Mississippi/3/2001 strain was also efficiently inactivated by LPO in a substrate-independent manner (log-based extent of inactivation: 6.16+/-0.27 for OSCN\(^-\) while 6.88+/-0.55 for OI\(^-\), \(n = 4\)) that was entirely blocked by catalase (Fig 3A). Although the A/Turkey/Kansas/4880/1980 H1N1 strain was also efficiently inactivated by LPO, its extent did not reach levels of significance (Fig 3A). While the four H1N1 influenza strains tested did not show a strong substrate preference in terms of inactivation by the cell-free \(\text{H}_2\text{O}_2/\text{LPO}/(\text{SCN}^-/\text{I}^-)\) system, they differed in their susceptibilities (Fig 3A). This is also shown in Fig 3B where the extent of virus inactivation is calculated as the catalase-dependent difference in viable viral titers (viral doses detected in presence of the full cell-free system are subtracted from viral doses recovered in presence of the full cell-free system plus catalase). Virus inactivation is calculated throughout the entire manuscript the same way.

**Iodide is the preferred LPO substrate to inactivate H3N2 IAV strains**

H3N2 IAV strains have become dominant causes of recent seasonal influenza epidemics [1]. The following four H3N2 influenza A strains were tested in the cell-free system for their LPO substrate specificities: A/Texas/50/2012, A/Wisconsin/67/2005, A/Aichi/2/1968 and A/Hong Kong/8/1968 (Table 1). These H3N2 strains circulate in the human population causing seasonal infections [26–29]. As shown in Fig 4A, OSCN\(^-\) treatment resulted in a decrease of infectious virus titers as measured by plaque assay between 1–3 logs for these H3N2 strains. While OSCN\(^-\)-mediated inactivation of A/Texas/50/2012 (\(p = 0.049\)) and A/Wisconsin/67/2005 (\(p = 0.023\)) were significant, there were no detectable significant differences for A/Aichi/2/68 (\(p = 0.155\)) and A/Hong Kong/8/68 (\(p = 0.123\)) (Fig 4A). Catalase reversed the H3N2 virus-inactivating effects of OSCN\(^-\) (Fig 4A). When OSCN\(^-\) was replaced by I\(^-\) as the LPO substrate in the cell-free system, it robustly enhanced viral inactivation that was significant (\(p<0.0005\))
for all four H3N2 IAVs (Fig 4A). The formation of OI⁻ by LPO resulted in reduced titers of A/ Wisconsin/67/2005 (4.21±0.25 log decrease, mean+/−S.E.M., n = 3), all other H3N2 strains were completely eliminated by the treatment (Fig 4A). The reversal of OI⁻ mediated H3N2 inactivation by catalase was highly significant (p <0.01) with all four strains tested (Fig 4A).

We determined H3N2 IAV inactivation in the cell-free system and found it to be significantly (p = 0.029) more robust when I⁻ was the LPO substrate used, compared to SCN⁻ (Fig 4B). To assess potential association of hemagglutinin or neuraminidase types of IAVs with their susceptibility to the LPO-based system, we compared viral inactivation and substrate preference of all nine IAV strains tested. When IAVs tested so far were grouped according to their HA types (H1 and H3) or NA types (N1, N2), no significant differences were seen between them regarding OSCN⁻ or OI⁻ mediated viral inactivation (Fig 5A and 5B, left and middle panels). To better characterize the substrate preference of LPO-mediated viral inactivation, we calculated a “SCN⁻ / I⁻ substrate preference ratio” or “OSCN⁻ / OI⁻ susceptibility ratio” for each strain by dividing the extent of SCN⁻ fueled virus inactivation by the extent of the I⁻ mediated one. When these SCN⁻ / I⁻ substrate preference ratios of all nine IAV strains were grouped according to their HA type (irrespective of NA), they were significantly (p = 0.0159) higher

Fig 3. Hypoiodite and hypothiocyanite are equally efficient in inactivating H1N1 influenza A viruses in the cell-free system. (A) The antiviral action of the cell-free H₂O₂/LPO/(SCN⁻/I⁻) system was tested against H1N1 influenza A strains, A/Brisbane/59/2007 (n = 3), A/California/04/2009 (n = 5), A/Mississippi/3/2001 (n = 4) and A/Turkey/Kansas/4880/1980 (n = 2). Viruses were incubated in the presence or absence of the components of the cell-free system as indicated for 1 hour and viral inactivation was assessed by plate-forming unit assay using MDCK cells. Mean+/−S.E.M. One-way ANOVA, Dunn’s multiple comparison test. (B) No significant difference can be observed in virus inactivation of the four H1N1 strains tested. Virus inactivation is calculated as the difference in viable viral titers between the sample containing the cell-free system and the sample containing the full, cell-free system plus catalase. Mean+/−S.E.M., n = 2–5. Mann-Whitney test. Ns, non-significant, *, p<0.05; **, p<0.01; ***, p<0.001. SCN⁻, thiocyanate; OSCN⁻, hypothiocyanite; I⁻, iodide; OI⁻, hypoiodite; LPO, lactoperoxidase; GO, glucose oxidase; MDCK, Madin-Darby canine kidney cells; PFU, plaque-forming unit; IAV, Influenza A virus.

https://doi.org/10.1371/journal.pone.0199167.g003
with H1 compared to H3 (Fig 5A, right panel). When the substrate preference ratios were grouped according to the NA type (irrespective of HA), we found no significant (p = 0.111) difference (Fig 5B, right panel). In summary, H3N2 IAV strains are also susceptible to the antimicrobial actions of LPO and show a surprising preference for I as the preferred substrate for inactivation that is associated with H1 and H3 hemagglutinin subtypes.

The influenza B virus strain, B/Yamagata/16/1988, is more susceptible to hypothiocyanite than hypoiodite

IBV strains primarily infect humans, do not have established animal reservoirs and pose little risk of pandemic infection [30,31]. IBV may cause seasonal influenza infections and co-circulate with IAV strains [30]. Importantly, IBV can dominate influenza seasons and is typically more resistant to antivirals than IAVs [30,32]. We investigated whether LPO present in our cell-free system can inactivate the influenza B strain, B/Yamagata/16/1988, a prototype strain of the Yamagata lineage of IBV strains [33]. As shown in Fig 6A, OSCN led to complete, highly significant (p<0.001) inactivation of the viral dose used. Using I as the LPO substrate, viral inactivation of IBV was significant (p = 0.021), but was reduced to a 1.6+/0.62 log
decrease (n = 5) in viral titers compared to 7.2+/−0.27 log drop (n = 5) in viral titers following OSCN− production (Fig 6A). As in the case of IAV strains, both, OSCN− and OI− mediated inactivation of this IBV strain was completely inhibited by catalase, as well (Fig 6A). Since the used dose of I− sustained only minor inactivation of the tested IBV strain, we increased the I−

Fig 5. Hemagglutinin subtypes are associated with LPO substrate preference supporting IAV inactivation. Susceptibilities of tested IAV strains to OSCN− and OI− in the cell-free system were compared according to their types of (A) hemagglutinin (H1, H3) and (B) neuraminidase (N1, N2). "SCN−/I− substrate preference ratios" were also calculated as described in the text for all nine IAV strains and compared among HA and NA types (upper and lower right panels). Ns, non-significant, *, p<0.05. SCN−, thiocyanate; OSCN−, hypothiocyanite; I−, iodide; OI−, hypoiodite; LPO, lactoperoxidase; GO, glucose oxidase; HA, hemagglutinin; NA, neuraminidase. The gray area highlights the only significant difference in the figure.

https://doi.org/10.1371/journal.pone.0199167.g005
concentration to 40 mM to explore the potential improvement of the antiviral action of LPO. Unexpectedly, we did not observe improved inactivation of the B/Yamagata/16/1988 strain by up to 100-fold higher I− doses (Fig 6B). Thus, the tested IBV strain showed a preference for SCN− as the LPO substrate for inactivation.

The substrate preference of influenza B strains for LPO-mediated inactivation is strain-dependent

To test whether the observed, marked difference in susceptibility to OSCN− versus OI− of the B/Yamagata/16/1988 strain (Fig 6A and 6B) is a unique feature of this strain or is generally true for all IBV strains, we tested two additional IBV strains. The B/Great Lakes/1739/1954 strain that also belongs to the Yamagata lineage [34] was efficiently inactivated (n = 5) by both, OSCN− (6.00±/−0.98 log decrease) and OI− (4.34+/−1.13 log decrease), with a slight preference to OSCN− (Fig 6A). The B/New York/1056/2003 IBV strain belongs to the Victoria lineage and has been isolated from a pharyngeal swab from a human with unspecified respiratory disease (BEI Resources). This Victoria lineage strain was equally inactivated by OSCN− (3.23+/−1.00
log decrease) and OI\(^-\) (3.23+/-.75 log decrease, n = 3) (Fig 6A). LPO-mediated inactivation of all three IBV strains was entirely blocked by catalase (Fig 6A). Although there is a trend towards OSCN\(^-\), data shown in Fig 6C did not find an overall significant difference between OSCN\(^-\)-fueled and OI\(^-\)-mediated inactivation of IBV strains.

**Influenza B viruses have a significantly higher OSCN\(^-\)/OI\(^-\) susceptibility ratio than influenza A strains**

To explore whether there are differences in the previous readouts between IAV and IBV strains, we compared susceptibilities to OSCN\(^-\) and OI\(^-\), as well as, their ratio called “OSCN\(^-\)/OI\(^-\) susceptibility ratio” between the IAV and IBV strains analyzed. As Fig 7 shows, there was no significant difference between the two viral species in their susceptibilities to the virucidal agents. However, we observed a significant difference (p = 0.0182) in their susceptibility ratios as shown in Fig 7 (right panel). All IAV strains had very low ratios (0.73+/-.13, mean+/-.S.E. M., n = 9) while IBV strains had much higher values (4.00+/-.23, mean+/-.S.E.M., n = 3) (Fig 7). Thus, IBV strains tend to be more sensitive to OSCN\(^-\) whereas IAV strains are equally sensitive to both LPO substrates or more susceptible to OI\(^-\).

**Substrate specificity map of influenza inactivation by LPO**

To summarize our results after surveying 12 different influenza strains for their susceptibilities and LPO substrate preferences in the \(\text{H}_2\text{O}_2/\text{LPO/SCN}^-/\text{I}^-\) system, we plotted our data as a “substrate preference or susceptibility map” shown in Fig 8. The X-axis represents the extent of viral inactivation that is associated with OSCN\(^-\), while the Y-axis represents the extent of viral inactivation by OI\(^-\). The higher the number, the more susceptible a particular virus strain is to the indicated, LPO-generated antiviral agent (Fig 8). The indicated diagonal crossing the

![Fig 7. Comparison of influenza A and B strains for their susceptibilities to the virucidal effects of LPO.](https://doi.org/10.1371/journal.pone.0199167.g007)
map from the lower left corner to the upper right corner indicates no substrate preference (Fig 8). The H1N2 influenza strain tested localizes to the upper right corner indicating high susceptibility to the LPO-based antimicrobial system with no considerable preference for the LPO substrate (Fig 8). All H1N1 strains appear on the diagonal showing no preference for the LPO substrate. While the A/Brisbane/59/2007 strain can be found in the lower left corner, the A/California/04/2009, A/Mississippi/3/2001, and A/Turkey/Kansas/4880/1980 strains, however, are all located in the upper right corner, close to the H1N2 strain, representing widely distinct susceptibilities of the tested H1N1 viruses towards the H$_2$O$_2$/LPO/(SCN-/I-) system. All four H3N2 influenza A strains showed a clear and noteworthy preference for I$^-$ as the LPO substrate for their inactivation in the cell-free system and were grouped together into an “H3N2 cluster” (Fig 8). The first IBV strain tested (B/Yamagata/16/1988) mapped into the lower right corner indicating its highly susceptible nature to OSCN$^-$ but almost resistance towards OI$^-$ (Fig 8). Two further IBV strains, however, failed to confirm this trend and localized to the vicinity of the center of the graph. Overall, our work represents an unexpected complexity of influenza virus inactivation by the H$_2$O$_2$/LPO/(SCN-/I-) system.

Discussion

Seasonal and pandemic infections by influenza viruses represent a major threat. Seasonal influenza viruses infect 5–15% of the human population annually, resulting in more than half a
million deaths worldwide [35]. Strain complexity, virus drift, and viral reassortment make it difficult to develop vaccines providing protection against a wide range of influenza strains. Current trivalent vaccines include one H1N1, one H3N2 IAV strain and one IBV strain of either the Yamagata or Victoria lineages [35]. Quadrivalent vaccines include two influenza B strains, one Yamagata and one Victoria strain, in addition to the two IAV strains [35]. The efficacy of the annual influenza vaccine varies widely from 10–60% [36], and the vaccine does not provide universal influenza virus protection [36]. Currently, all antivirals face the problem of increasing drug resistance [37]. Therefore, there is an urgent need to find novel mechanisms by which influenza can be fought, preferably in a strain-independent fashion.

The \( \text{H}_2\text{O}_2/\text{LPO}/(\text{SCN}^-/\text{I}^-) \) system represents an oxidative, fast-reacting mechanism of the respiratory innate immune system that is capable of killing or inactivating a wide range of pathogens. Our results reported here are one of the first ones to document its efficacy against influenza virus. Our prior results established that the \( \text{H}_2\text{O}_2/\text{LPO/SCN}^- \) system assembled in vitro cultures of differentiated, human and rat, tracheobronchial epithelial cells inactivates the A/Swine/Illinois/02860/2009 influenza A strain [9]. Here we confirmed that \( \text{H}_2\text{O}_2/\text{LPO/SCN}^- \) system behaves in a very similar fashion and inactivates the same H1N2 strain under cell-free experimental conditions. This cell-free system provides us with an important tool to address the specificity and the mechanism of action of the LPO-based system against influenza viruses. It is important to emphasize that influenza viruses are inactivated by the \( \text{H}_2\text{O}_2/\text{LPO/SCN}^- \) system in both the cell-free and airway epithelial model [9] in less than 60 minutes. Very few, if any, mechanism of the innate immune system reacts so fast and efficiently.

In the current work we expanded our observation made on the IAV H1N2 strain to other influenza strains. Our central focus has been to address the question of whether SCN\(^-\) or I\(^-\) serves as a better substrate for the anti-influenza action of LPO. We revealed a LPO substrate preference of influenza inactivation that appears more complex than expected. Based on the current survey of influenza strains we conclude that H3N2 IAV strains are inactivated by OI\(^-\) more effectively than by OSCN\(^-\). This is presented as an “H3N2 cluster” on LPO’s substrate preference map (Fig 8). We did not find this bias towards I\(^-\) in case of the other IAVs (H1N1 and H1N2) that were inactivated by the LPO substrates. The potential explanation for this is unclear at the moment but redox-sensitive disulfide bonds may be different among HA or NA subtypes that could help explain this observation [38, 39]. Differences in OI\(^-\) or OSCN\(^-\) mediated oxidative modifications of these bonds could lead to altered virion disassembly or inhibition of viral entry into host cells [39, 40]. Oxidative stress has been shown to inactivate influenza viruses [41]. Oxidative damage of the lipid components of the viral envelope or the nucleoprotein could be also the results of the antimicrobial action of LPO [41]. Differences in susceptibilities of influenza viruses to polyphenols were linked to viral envelope glycoproteins [42]. OI\(^-\) has a higher oxidative strength than OSCN\(^-\) [43]. While the main potential targets of OSCN\(^-\)/HOSCN are certain SH groups, OI\(^-\)/HOI can target SH groups, NAD(P)H, reduced pyridine nucleotides, thioether groups and NH\(_2\) groups [43]. These molecular differences could form the basis for the observed inactivation patterns of influenza viruses in our study. The virucidal effect of OSCN\(^-\) and OI\(^-\) may be due to their ability to either interact with viral HA or NA directly and interfere with viral cell entry or to cross the outer layer of the viral envelop before oxidizing critical viral elements inside the virion. We know that beneath the lipid membrane of the influenza virus, a viral protein called M1 matrix protein is expressed and may be reacting with OSCN\(^-\) or OI\(^-\) and interfere with viral infectivity [44]. Other viral proteins that are cysteine-rich may be the targets of these antiviral agents. In bacteria, for example, the reported bacterial targets of OSCN\(^-\) are critical cysteine residues found in glycolytic enzymes, such as glyceraldehyde triphosphate dehydrogenase, hexokinase, glycose-6-phosphate dehydrogenase, and aldolase leading to the hypothesis that OSCN\(^-\) effect on
bacterial growth is glycolysis-mediated [45]. Glucose transport and respiration may also be the target of OSCN⁻ and OI⁻. It has been reported to inhibit the activity of urease, which is critical to the ability of H. pylori to alkalinize gastric juice and colonize the stomach [46].

IBVs can cause symptoms similar to IAVs in humans, and are responsible for a large proportion of seasonal influenza infections [30, 32]. Far less is known regarding the viral and host determinants of IBV disease pathogenicity [30, 32]. The immune response against IBV is affected by yearly trivalent or quadrivalent vaccines and typically is weaker in humans than that against IAVs [30]. NA inhibitors that work well against most strains of IAV are typically less effective for IBVs [30]. Therefore, novel approaches are needed to confront IBV. Our results show that the B/Yamagata/16/1988 strain is sensitive against the H₂O₂/LPO/SCN⁻ system but remains more resistant against the H₂O₂/LPO/I⁻ system. After testing two other IBV strains, this pattern failed to be confirmed suggesting that it could be strain-specific. Testing a larger number of IBV strains is needed for a firmer conclusion. Nevertheless, our findings are the first to show that the H₂O₂/LPO/SCN⁻ antimicrobial system efficiently inactivates IBV strains, as well.

Given the wealth of historical data showing that these LPO-generated products have antimicrobial effects, they could be used for either therapeutic or prophylactic supplementation before infection or drugs, in combination with current anti-influenza therapies to enhance viral elimination and diminish inflammation. SCN⁻ is present in the diet and no serious adverse effects of SCN⁻ in humans have been reported at physiological concentrations (reviewed in [47]). Iodide intake has already been proposed to improve viral clearance but has several hurdles. While lower dose of iodide intake is safe and associated with normal thyroid function, recent works have proven that alterations in thyroid function are associated with high iodide supplementation in maternal rats and their offspring [48]. Other findings show that treatment in vivo with an excess of iodide can induce the blockade of thyroid hormone biosynthesis [49] and excess of iodide could induce mononuclear infiltration in salivary gland as recently indicated in a Swiss albino mouse model [50]. These results question whether iodide supplementation would work to boost anti-influenza defenses.

In summary, the findings presented here shows that the H₂O₂/LPO/(SCN⁻/I⁻) system robustly inactivates a wide range of influenza viruses that are the major circulating serotypes and species causing epidemics and are also components of the annual influenza vaccine. These results are very encouraging considering the likely contribution of this mechanism to in vivo influenza clearance and its potential as a target for pharmaceutical intervention.

Supporting information

S1 Data. Plaque forming unit results. The original data of the plaque forming unit assays using MDCK cells of the virus strains tested in this work are shown for each experiment organized according to the figures.

(XLSX)

Acknowledgments

The authors would like to thank Jackelyn Crabtree working in the Tripp laboratory for her help with ordering and initial propagation of some of the influenza strains.

Author Contributions

Conceptualization: Ralph A. Tripp, Balázs Rada.

Data curation: Urmi Patel, Aaron Gingerich, Lauren Widman.
Formal analysis: Aaron Gingerich, Balázs Rada.

Funding acquisition: Ralph A. Tripp, Balázs Rada.

Investigation: Urmi Patel, Ralph A. Tripp, Balázs Rada.

Methodology: Urmi Patel, Aaron Gingerich.

Project administration: Balázs Rada.

Resources: Aaron Gingerich, Ralph A. Tripp, Balázs Rada.

Supervision: Aaron Gingerich, Ralph A. Tripp, Balázs Rada.

Validation: Ralph A. Tripp, Balázs Rada.

Visualization: Balázs Rada.

Writing – original draft: Balázs Rada.

Writing – review & editing: Urmi Patel, Aaron Gingerich, Lauren Widman, Demba Sarr, Ralph A. Tripp, Balázs Rada.

References

1. Review of the 2014–2015 influenza season in the northern hemisphere. Wkly Epidemiol Rec. 2015; 90(23):281–96. PMID: 26050269

2. Hsieh CS, Lee HM, Lio CW. Selection of regulatory T cells in the thymus. Nat Rev Immunol. 2012; 12:157–67. https://doi.org/10.1038/nri3155 PMID: 22322317

3. Lowen AC. Constraints, Drivers, and Implications of Influenza A Virus Reassortment. Annu Rev Virol. 2017; 4(1):105–21. https://doi.org/10.1146/annurev-virology-101416-014726 PMID: 28548881

4. Pinsent A, Fraser C, Ferguson NM, Riley S. A systematic review of reported reassortant viral lineages of influenza A. BMC Infect Dis. 2016; 16:3. https://doi.org/10.1186/s12879-015-1298-9 PMID: 26732146

5. Spanakis N, Pitririga V, Gennimata V, Tsakris A. A review of neuraminidase inhibitor susceptibility in influenza strains. Expert Rev Anti Infect Ther. 2014; 12(11):1325–36. https://doi.org/10.1586/14787210.2014.966083 PMID: 25301229

6. Londino JD, Lazrak A, Collawn JF, Bebok Z, Harrod KS, Matalon S. Influenza virus infection alters ion channel function of airway and alveolar cells: mechanisms and physiological sequelae. Am J Physiol Lung Cell Mol Physiol. 2017; 313(5):L845–L58. https://doi.org/10.1152/ajplung.00244.2017 PMID: 28775098

7. Herold S, Becker C, Ridge KM, Budinger GR. Influenza virus-induced lung injury: pathogenesis and implications for treatment. Eur Respir J. 2015; 45(5):1463–78. https://doi.org/10.1183/09031936.00186214 PMID: 25792631

8. Geiszt M, Witta J, Baffi J, Lekstrom K, Leto TL. Dual oxidases represent novel hydrogen peroxide sources supporting mucosal surface host defense. FASEB J. 2003; 17(1):1502–4. https://doi.org/10.1096/fj.02-1104fje PMID: 12824283

9. Gingerich A, Pang L, Hanson J, Dlugolenski D, Streich R, Lafontaine ER, et al. Hypothiocyanite produced by human and rat respiratory epithelial cells inactivates extracellular H1N2 influenza A virus. Inflamn Res. 2016; 65(1):71–80. https://doi.org/10.1007/s00011-015-0892-z PMID: 26608498

10. Rada B, Leto TL. Oxidative innate immune defenses by Nox/Duox family NADPH oxidases. Contrib Microbiol. 2008; 15:164–87. https://doi.org/10.1159/000136357 PMID: 18511861

11. Rada B, Leto TL. Redox warfare between airway epithelial cells and Pseudomonas: dual oxidase versus pyocyanin. Immunol Res. 2009; 43(1–3):198–209. https://doi.org/10.1007/s12026-008-8071-8 PMID: 18979077

12. Gerson C, Sabater J, Scuri M, Torbati A, Coffey R, Abraham JW, et al. The lactoperoxidase system functions in bacterial clearance of airways. Am J Respir Cell Mol Biol. 2000; 22(6):665–71. https://doi.org/10.1165/ajrccm.22.6.8936 PMID: 10837362

13. Cegolon L, Salata C, Piccoli E, Juarez V, Palu G, Mastrangelo G, et al. In vitro antiviral activity of hypothiocyanite against A/H1N1/2009 pandemic influenza virus. Int J Hyg Environ Health. 2014; 217(1):17–22. https://doi.org/10.1016/j.ijheh.2013.03.001 PMID: 23540468
14. Sharma S, Singh AK, Kaushik S, Sinha M, Singh RP, Sharma P, et al. Lactoperoxidase: structural insights into the function, ligand binding and inhibition. Int J Biochem Mol Biol. 2013; 4(3):108–28. PMID: 24049667

15. Ahariz M, Courtis P. Candida albicans susceptibility to lactoperoxidase-generated hypoiodite. Clin Cosmet Investig Dent. 2010; 2:69–78. PMID: 23662084

16. Schlorke D, Atosoo J, Flemmig J, Lilus EM, Arnhold J. Impact of cyanogen iodide in killing of Escherichia coli by the lactoperoxidase-hydrogen peroxide-(pseudo)halide system. Free Radic Res. 2016; 50(12):1287–95. https://doi.org/10.1080/10715762.2016.1235788 PMID: 27629563

17. Dlugolen ski D, Jones L, Howerth E, Wentworth D, Tompkins SM, Tripp RA. Swine Influenza Virus PA and Neuraminidase Gene Reassortment into Human H1N1 Influenza Virus Is Associated with an Altered Pathogenic Phenotype Linked to Increased MIP-2 Expression. J Virol. 2015; 89(10):5651–67. https://doi.org/10.1128/JVI.00087-15 PMID: 25762737

18. Wijkstrom-Freil C, El-Chema ly S, Ali-Rachedi R, Gerson C, Cobas MA, Forteza R, et al. Lactoperoxidase and human airway host defense. Am J Respir Cell Mol Biol. 2003; 29(2):206–12. https://doi.org/10.1165/rcmb.2002-0152OC PMID: 12626341

19. Conner GE, Salathe M, Forteza R. Lactoperoxidase and hydrogen peroxide metabolism in the airway. Am J Respir Crit Care Med. 2002; 166(12 Pt 2):S57–61.

20. Rada B, Lekstrom K, Damian S, Dupuy C, Leto TL. The Pseudomonas toxin pyocyanin inhibits the dual oxidase-based antimicrobial system as it imposes oxidative stress on airway epithelial cells. J Immunol. 2008; 181(7):4883–93. PMID: 18802092

21. Rada B, Leto TL. Characterization of hydrogen peroxide production by Duox in bronchial epithelial cells exposed to Pseudomonas aeruginosa. FEBS Lett. 2010; 584(5):917–22. https://doi.org/10.1016/j.feslet.2010.01.025 PMID: 20085766

22. Derscheid RJ, van Geelen A, Berkebile AR, Gallup JM, Hostetter SJ, Banfi B, et al. Increased concentration of iodide in airway secretions is associated with reduced respiratory syncytial virus disease severity. Am J Respir Cell Mol Biol. 2014; 50(2):389–97. https://doi.org/10.1165/rcmb.2012-0529OC PMID: 24053146

23. Retamal M, Abed Y, Corbeil J, Boivin G. Epitope mapping of the 2009 pandemic and the A/Brisbane/59/2007 seasonal (H1N1) influenza virus haemagglutinins using mAbs and escape mutants. J Gen Virol. 2014; 95(11):2377–89. https://doi.org/10.1099/vir.0.067819-0 PMID: 25078301

24. Clark AM, DeDiego ML, Anderson CS, Wang J, Yang H, Nogales A, et al. Antigenicity of the 2015–2016 seasonal H1N1 human influenza virus HA and NA proteins. PLoS One. 2017; 12(11):e0188267. https://doi.org/10.1371/journal.pone.0188267 PMID: 29145498

25. Kilbourne ED, Taylor AH, Whitacker CW, Sahai R, Caton AJ. Hemagglutinin polymorphism as the basis for low- and high-yield phenotypes of swine influenza virus. Proc Natl Acad Sci U S A. 1988; 85(20):7782–5. PMID: 3174662

26. Manelboim M, Glatman-Freeman A, Drori Y, Sherbany H, Pando R, Setty H, et al. Ineffectiveness of the 2014–2015 H3N2 influenza vaccine. Oncotarget. 2016; 7(2):1185–92. https://doi.org/10.18632/oncotarget.6746 PMID: 26716420

27. Sobel Leonard A, McClain MT, Smith GJ, Wentworth DE, Halpin RA, Lin X, et al. Deep Sequencing of Influenza A Virus from a Human Challenge Study Reveals a Selective Bottleneck and Only Limited Intrahost Genetic Diversification. J Virol. 2016; 90(24):11247–58. https://doi.org/10.1128/JVI.01567-16 PMID: 27707932

28. Jegaskanda S, Job ER, Kramski M, Laurie K, Isitman G, de Rose R, et al. Cross-reactive influenza-specific antibody-dependent cellular cytolysis antibodies in the absence of neutralizing antibodies. J Immunol. 2013; 190(4):1837–48. https://doi.org/10.4049/jimmunol.1201574 PMID: 23319732

29. Peng W, de Vries RP, Grant OC, Thompson AJ, McBride R, Tsogtbaatar B, et al. Recent H3N2 Viruses Have Evolved Specificity for Extended, Branched Human-type Receptors, Conferring Potential for Increased Avidity. Cell Host Microbe. 2017; 21(1):23–34. https://doi.org/10.1016/j.chom.2016.11.004 PMID: 28017661

30. Koutsakos M, Nguyen TH, Barclay WS, Kedzierska K. Knowns and unknowns of influenza B viruses. Future Microbiol. 2016; 11(1):119–35. https://doi.org/10.2217/fmb.15.120 PMID: 26684590

31. Jackson D, Elderfield RA, Barclay WS. Molecular studies of influenza B virus in the reverse genetics era. J Gen Virol. 2011; 92(1):1–17. https://doi.org/10.1099/vir.0.026187-0 PMID: 20926635

32. Burtnham AJ, Baranovich T, Govorkova EA. Neuraminidase inhibitors for influenza B virus infection: efficacy and resistance. Antiviral Res. 2013; 100(2):520–34. https://doi.org/10.1016/j.antiviral.2013.08.023 PMID: 24013000

33. Verma S, Soto J, Vasudevan A, Schmeisser F, Alvarado-Facundo E, Wang W, et al. Determination of influenza B identity and potency in quadrivalent inactivated influenza vaccines using lineage-specific
monoclonal antibodies. PLoS One. 2017; 12(4):e0175733. https://doi.org/10.1371/journal.pone.0175733 PMID: 28423025
34. Mogabgab WJ, Green IJ, Dierkhising OC, Phillips IA. Isolation and cytopathogenic effect of influenza B viruses in monkey kidney cultures. Proc Soc Exp Biol Med. 1955; 89(4):654–9. PMID: 13254857
35. Stohr K. Influenza—WHO cares. Lancet Infect Dis. 2002; 2(9):517. PMID: 12206966
36. Belongia EA, Skowronski DM, McLean HQ, Chambers C, Sundaram ME, De Serres G. Repeated annual influenza vaccination and vaccine effectiveness: review of evidence. Expert Rev Vaccines. 2017; 16(7):1–14.
37. Hussain M, Galvin HD, Haw TY, Nutsford AN, Husain M. Drug resistance in influenza A virus: the epidemiology and management. Infect Drug Resis. 2017; 10:121–34. https://doi.org/10.2147/IDR.S105473 PMID: 28458567
38. Kemble GW, Bodian DL, Rose J, Wilson IA, White JM. Intermonomer disulfide bonds impair the fusion activity of influenza virus hemagglutinin. J Virol. 1992; 66(8):4940–50. PMID: 1629960
39. Ogata N. Inactivation of influenza virus haemagglutinin by chlorine dioxide: oxidation of the conserved tryptophan 153 residue in the receptor-binding site. J Gen Virol. 2012; 93(Pt 12):2558–63. https://doi.org/10.1099/vir.0.044263-0 PMID: 22933663
40. Sriwilaiparoon N, Wilairat P, Hiramatsu H, Takahashi T, Suzuki T, Ito M, et al. Mechanisms of the action of povidone-iodine against human and avian influenza A viruses: its effects on hemagglutination and sialidase activities. Virol J. 2009; 6:124. https://doi.org/10.1186/1743-422X-6-124 PMID: 19678928
41. Sakudo A, Misawa T, Shimizu N, Imanishi Y. N(2) gas plasma inactivates influenza virus mediated by oxidative stress. Front Biosci (Elite Ed). 2014; 6:69–79.
42. Sundararajan A, Ganapathy R, Huan L, Dunlap JR, Webby RJ, Kotwal GJ, et al. Influenza virus variation in susceptibility to inactivation by pomegranate polyphenols is determined by envelope glycoproteins. Antiviral Res. 2010; 88(1):1–9. https://doi.org/10.1016/j.antiviral.2010.06.014 PMID: 20637243
43. Bafort F, Parisi O, Perraudin JP, Iijakki MH. Mode of action of lactoperoxidase as related to its antimicrobial activity: a review. Enzyme Res. 2014; 2014:517164. https://doi.org/10.1155/2014/517164 PMID: 25309750
44. Korydykova LV, Shytikova EV, Baratova LA, Svergun DI, Batishchev OV. Matrix proteins of enveloped viruses: a case study of Influenza A virus M1 protein. J Biomol Struct Dyn. 2018:1–20.
45. Nagy P, Jameson GN, Winterbourn CC. Kinetics and mechanisms of the reaction of hypohypocyanate acid with 5-thio-2-nitrobenzoic acid and reduced glutathione. Chem Res Toxicol. 2009; 22(11):1833–40. https://doi.org/10.1021/tr900249d PMID: 19821602
46. Das D, De PK, Banerjee RK. Thiocyanate, a plausible physiological electron donor of gastric peroxidase. Biochem J. 1995, 305 (Pt 1):59–64.
47. Higdon JV, Delage B, Williams DE, Dashwood RH. Cruciferous vegetables and human cancer risk: epidemiologic evidence and mechanistic basis. Pharmacol Res. 2007; 55(3):224–36. https://doi.org/10.1016/j.phrs.2007.01.009 PMID: 17317210
48. Liang X, Feng Y, Lin L, Abeysekera IR, Iqbal U, Wang T, et al. Thyroid function alterations attributed to high iodide supplementation in maternal rats and their offspring. J Trace Elem Med Biol. 2018; 47:89–97. https://doi.org/10.1016/j.jtemb.2018.01.018 PMID: 29544812
49. Li HS, Carayanniotis G. Induction of goitrous hypothyroidism by dietary iodide in SJL mice. Endocrinology. 2007; 148(6):2747–52. https://doi.org/10.1210/en.2007-0082 PMID: 17347303
50. Ross GR, Fabbri S, Russo M, Gomez A, Japaze H, Gonzalez SN, et al. Effect of Excess Iodide Intake on Salivary Glands in a Swiss Albino Mouse Model. Biomed Res Int. 2017; 2017:6302869. https://doi.org/10.1155/2017/6302869 PMID: 29250546